Shionogi's Xocova effective in preventing symptomatic COVID-19: study
The Phase 3 study consisted of 2,400 participants in Asia, Africa, South America and the US. Xocova is also known as ...
朝日新聞社2y
Shionogi’s anti-COVID-19 tablet wins emergency approval for use
The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...
朝日新聞社2y
Panel again does not approve Shionogi’s pill to treat COVID-19
The name of the pill is Xocova, and its generic name is ensitrelvir ... Patients will be advised to take one tablet a day for five days if the pill is approved. Shionogi requested at the ...
U.S. News & World Report29d
Japan's Shionogi Says Phase 3 Study Showed COVID Pill Reduces Transmission
Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in ...
BioWorld22d
Shionogi finds positive data on ensitrelvir for COVID-19
Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the ...